Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies.
- DOI
- 10.1182/bloodadvances.2024015157
- Published
- 2025-04-01
- Container
- Blood Adv
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2024015157,
title = {Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies.},
author = {Shahid S and Prockop SE and Flynn GC and Mauguen A and White CO and Bieler J and McAvoy D and Hosszu K and Cancio MI and Jakubowski AA and Scaradavou A and Boelens JJ and Sauter CS and Perales MA and Giralt SA and Taylor C and Chaudhari J and Wang X and Rivière I and Sadelain M and Brentjens RJ and Kernan NA and O'Reilly RJ and Curran KJ.},
year = {2025},
journal = {Blood Adv},
doi = {10.1182/bloodadvances.2024015157},
url = {https://doi.org/10.1182/bloodadvances.2024015157}
}RIS
TY - JOUR TI - Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies. AU - Shahid S AU - Prockop SE AU - Flynn GC AU - Mauguen A AU - White CO AU - Bieler J AU - McAvoy D AU - Hosszu K AU - Cancio MI AU - Jakubowski AA AU - Scaradavou A AU - Boelens JJ AU - Sauter CS AU - Perales MA AU - Giralt SA AU - Taylor C AU - Chaudhari J AU - Wang X AU - Rivière I AU - Sadelain M AU - Brentjens RJ AU - Kernan NA AU - O'Reilly RJ AU - Curran KJ. PY - 2025 JO - Blood Adv DO - 10.1182/bloodadvances.2024015157 UR - https://doi.org/10.1182/bloodadvances.2024015157 ER -
APA
S, S., SE, P., GC, F., A, M., CO, W., J, B., D, M., K, H., MI, C., AA, J., A, S., JJ, B., CS, S., MA, P., SA, G., C, T., J, C., X, W., I, R., M, S., RJ, B., NA, K., RJ, O., & KJ., C. (2025). Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies.. Blood Adv. https://doi.org/10.1182/bloodadvances.2024015157
Source records
- europe-pmc · retrieved 2026-09-27T02:08:03.344Z
- doaj · retrieved 2026-09-27T02:08:03.352Z